Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis is managing 1 pending office action in the Medical Devices & Mechanical Engineering technology area. This action is assigned to 1 distinct examiner, MALDONADO, STEVEN, who is the busiest examiner with 1 pending action. This 1 to 1 relationship between the pending action and the examiner indicates a very specific and singular point of engagement with the patent office for the company's current Medical Devices & Mechanical Engineering interests.
The prosecution is situated within 1 distinct art unit, matching the count of examiners and pending actions. For a practitioner, this concentration means that the company's current success in the Medical Devices & Mechanical Engineering sector is entirely dependent on the review of MALDONADO, STEVEN. The lack of multiple art units or examiners suggests a narrow administrative footprint, which may simplify communication but also increases the impact of a single examiner's perspective on the portfolio's immediate outcomes. This focused approach ensures that all current intellectual property efforts are channeled through a single, specialized path within the patent office.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 100.0% | +0.0% |
| JACKSON III, WALTER | 1 | 100.0% | +0.0% |
| DAVIS, JASON GREGORY | 1 | 74.4% | +17.8% |
| SHUPE, ELIZABETH A | 1 | 66.2% | +44.2% |
| WEBB, WALTER E | 1 | 46.3% | +18.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923671 | FLUID INJECTION DEVICE FOR INJECTING A FLUID BEHIND THE TYMPANIC MEMBRANE | DAVIS, JASON GREGORY | 167d overdue |
| 18836940 | AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER | AGGARWAL, SAHIL CHANDER | — |
| 18708092 | DGAT1/2-INDEPENDENT ENZYME SYNTHESIZING STORAGE LIPIDS (DIESL) | JACKSON III, WALTER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923671 | FLUID INJECTION DEVICE FOR INJECTING A FLUID BEHIND THE TYMPANIC MEMBRANE | DAVIS, JASON GREGORY | 167d overdue |
| 17619076 | SODIUM THIOSULFATE GEL FOR PREVENTING OR REDUCING HEARING LOSS | WEBB, WALTER E | 12d |
| 17909553 | MODULATING ANTI-TUMOR IMMUNITY | SHUPE, ELIZABETH A | — |
| Art Unit | Apps |
|---|---|
| 3745 | 1 |
| 1643 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836940 | AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER | AGGARWAL, SAHIL CHANDER | — | §102§103 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18708092 | DGAT1/2-INDEPENDENT ENZYME SYNTHESIZING STORAGE LIPIDS (DIESL) | JACKSON III, WALTER | — | §102§103§112 | Non-Final OA | — | Pending | May 07, 2024 |
| 17923671 | FLUID INJECTION DEVICE FOR INJECTING A FLUID BEHIND THE TYMPANIC MEMBRANE | DAVIS, JASON GREGORY | 3745 | §102§103§112 | Non-Final OA | 167d overdue | Pending | Nov 07, 2022 |
| 17909553 | MODULATING ANTI-TUMOR IMMUNITY | SHUPE, ELIZABETH A | 1643 | §103 | Final Rejection | — | Pending | Sep 06, 2022 |
| 17619076 | SODIUM THIOSULFATE GEL FOR PREVENTING OR REDUCING HEARING LOSS | WEBB, WALTER E | 1612 | §103 | Final Rejection | 12d | Pending | Dec 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial